Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Digital Realty Trust, Inc. (DLR) Price & Performance

Ascendis Pharma A/STrade
Digital Realty Trust, Inc.Trade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Digital Realty Trust, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Digital Realty Trust, Inc. trades at $191.45 (market cap $70.79B). The key difference: Digital Realty Trust, Inc. is far larger — about 4.2× Ascendis Pharma A/S's market cap, and Digital Realty Trust, Inc. pays a 2.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDDLR
Market Cap
$16.78B$70.79B
Sector
HealthReal Estate
52-Week High
$277.18$203.91
52-Week Low
$189.74$147.93
Enterprise Value
$17.15B$89.50B
Dividend Yield
2.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.

ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.

Digital Realty Trust, Inc.

Digital Realty Trust (DLR) trades at $193.80, up 0.64% today, with a bullish technical signal from moving averages and support at $192. Recent Q2 2026 earnings beat expectations with core FFO of $2.13 per share, driven by record leasing and a $1.9 billion backlog. The company raised its 2026 guidance, reflecting strong AI-driven data center demand. Valuation ratios are elevated, with a P/E of 245.32 and P/S of 25.47, indicating premium pricing relative to earnings and sales.

DLR's outlook is positive due to robust AI infrastructure demand and raised guidance, but high valuation and interest rate sensitivity pose risks. Analyst consensus is bullish with a $216.56 price target, though net cash flow turned negative in 2025. Investors should weigh growth potential against execution risks in a competitive sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Digital Realty Trust, Inc.

Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.

Read more on DLR